6月12日中银创新医疗混合A净值增长4.23%，今年来累计上涨68.97%

Group 1 - The core point of the article highlights the performance of the Zhongyin Innovation Medical Mixed A fund, which has shown significant growth in its net value and returns over various time frames [1] - As of June 12, 2025, the fund's latest net value is 2.0332 yuan, reflecting a growth of 4.23%. The fund has achieved a return of 29.59% over the past month, 53.60% over the past six months, and 68.97% year-to-date, ranking 77 out of 4655, 28 out of 4508, and 26 out of 4536 respectively [1] - The top ten stock holdings of the fund account for a total of 70.44%, with significant positions in companies such as Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] Group 2 - The Zhongyin Innovation Medical Mixed A fund was established on November 13, 2019, and as of March 31, 2025, it has a total asset size of 2.613 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry, including roles at Taikang Asset Management and Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed A fund since July 1, 2022, and has also taken on management roles for other funds within the Zhongyin family [2]